|Articles|March 1, 2018
- BioPharm International-03-01-2018
- Volume 31
- Issue 3
BioPharm International, March 2018 Issue (PDF)
Click the title above to open the BioPharm International March 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 7 years ago
FDA Heightens Drive for Transparencyover 7 years ago
Current Challenges in Bioprocesses Developmentover 7 years ago
Characterizing a Bioprocess with Advanced Data Analyticsover 7 years ago
Computerized Systems Validationover 7 years ago
Regulatory Role in Bio/Pharma Progressover 7 years ago
Poseidon Takes on the Pharma Supply Chainover 7 years ago
Identifying and Controlling CPPs and CMAsover 7 years ago
Employing Spectroscopic Tools in Downstream Process Controlover 7 years ago
Biologic NMEs Maintain Strong Presence in 2017 Drug ApprovalsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
5
